Apogee (NASDAQ: APGE) director swaps options for cash in AbbVie deal
Apogee Therapeutics (APGE) director Lisa Bollinger cashed out vested stock options in a merger deal with AbbVie. The options, covering 48,780 shares, were canceled and exchanged for $135.11 per share minus exercise prices ranging from $41.66 to $85.00. The transaction occurred on September 3, 2026, under a merger agreement dated June 18, 2026.
How this was made
The 30-second read
Why it matters
The filing provides the first public detail on how the merger consideration is applied to insider options, offering modest insight into transaction economics.
Market read
Primary insider filing; modest relevance for traders monitoring the merger.
What to watch
Potential tax implications for the director and any related lock‑up provisions are not disclosed.
Background
Apogee Therapeutics (NASDAQ:APGE) is completing a merger with AbbVie. The Form 4 filing details a director's option disposition.
Ticker impact
Director Lisa Bollinger cashed out vested stock options in the AbbVie merger, disclosing the cash consideration per share.
Minor short-term price pressure as insiders sell option value.
Insider disposition of options is a primary filing but the monetary amount is modest, limiting market impact.
Market effects
Limited; reflects merger activity in biotech sector but no broader sector shift.
US biotech market only.
Low; the filing is company‑specific.
Counterpoint
The option cash‑out may be viewed as a sign of confidence in merger value, supporting a short‑term rally.
Key entities
- CompanyApogee Therapeutics
Biotech firm merging with AbbVie.
- IndividualLisa Bollinger
Director of Apogee who disposed of vested options.
- CompanyAbbVie Inc.
Merger partner providing the cash consideration.
